Complete financial analysis of Samjin Pharmaceuticals Co., Ltd. (005500.KS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Samjin Pharmaceuticals Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Tingo Group, Inc. (TIO) Income Statement Analysis – Financial Results
- Sparinvest – Index Sektor Industri Kl (SPVBEUKL.CO) Income Statement Analysis – Financial Results
- Yext, Inc. (YEXT) Income Statement Analysis – Financial Results
- Synbio Tech Inc. (1295.TWO) Income Statement Analysis – Financial Results
- Land and Houses Freehold and Leasehold Property Fund (LHPF.BK) Income Statement Analysis – Financial Results
Samjin Pharmaceuticals Co., Ltd. (005500.KS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.samjinpharm.co.kr
About Samjin Pharmaceuticals Co., Ltd.
Samjin Pharmaceuticals Co., Ltd. engages in the research and development of pharmaceutical products in Korea. The company's products include SA001, a clinical Phase II product for the treatment of dry eye and sjogren syndrome; SJP1803/1804, a preclinical stage product for the treatment of macular degeneration; SJP601 and SJP1602 preclinical stage products for the treatment of cancer; SPJ1604 and SPJ003 clinical phase products for the treatment of cancer and diabetes; and SJP1901, SJP1902, SJP1801, and SJP006 biological testing stage products for the treatment of cancer, fibrosis, cancer immunotherapy, alzheimer's disease, Parkinson's disease, and anti-viral disease. The company was founded in 1968 and is headquartered in Seoul, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 292.13B | 274.03B | 250.07B | 235.16B | 241.93B | 260.02B | 245.27B | 239.31B | 216.51B | 201.31B | 192.01B | 185.70B | 201.76B | 200.41B | 165.39B | 148.00B | 137.11B |
| Cost of Revenue | 146.24B | 156.30B | 132.24B | 124.65B | 121.21B | 117.24B | 109.29B | 109.97B | 96.67B | 89.31B | 75.04B | 77.52B | 80.32B | 79.88B | 69.27B | 56.26B | 50.83B |
| Gross Profit | 145.89B | 117.73B | 117.83B | 110.52B | 120.71B | 142.78B | 135.98B | 129.35B | 119.84B | 111.99B | 116.97B | 108.18B | 121.44B | 120.53B | 96.12B | 91.74B | 86.28B |
| Gross Profit Ratio | 49.94% | 42.96% | 47.12% | 47.00% | 49.90% | 54.91% | 55.44% | 54.05% | 55.35% | 55.63% | 60.92% | 58.26% | 60.19% | 60.14% | 58.12% | 61.99% | 62.93% |
| Research & Development | 4.17B | 3.66B | 2.58B | 1.51B | 2.60B | 3.74B | 3.65B | 2.80B | 2.77B | 3.29B | 7.62B | 11.03B | 10.43B | 8.78B | 6.12B | 4.02B | 3.07B |
| General & Administrative | 15.15B | 17.14B | 15.05B | 13.96B | 13.44B | 19.70B | 21.63B | 22.22B | 23.47B | 22.62B | 23.45B | 23.43B | 22.12B | 19.70B | 19.73B | 19.17B | 17.51B |
| Selling & Marketing | 26.31B | 25.57B | 19.71B | 19.07B | 15.16B | 20.08B | 24.08B | 24.21B | 22.50B | 21.09B | 20.99B | 24.14B | 32.57B | 36.71B | 31.82B | 30.42B | 25.88B |
| SG&A | 41.46B | 42.71B | 34.76B | 33.02B | 28.60B | 39.78B | 45.71B | 46.43B | 45.98B | 43.72B | 44.45B | 47.56B | 54.69B | 56.41B | 51.56B | 49.60B | 43.39B |
| Other Expenses | 50.57B | 48.18B | 46.58B | 43.74B | 44.62B | 90.76M | -392.10M | -292.59M | -90.11M | -127.69M | 161.47M | -777.85M | 32.33B | -79.63M | -587.08M | -1.24B | -2.97B |
| Operating Expenses | 96.20B | 94.55B | 83.92B | 78.27B | 75.82B | 83.24B | 89.04B | 87.29B | 83.87B | 80.41B | 86.87B | 90.86B | 97.44B | 98.45B | 84.12B | 79.16B | 69.57B |
| Cost & Expenses | 271.64B | 250.85B | 216.16B | 202.92B | 197.03B | 200.47B | 198.33B | 197.25B | 180.55B | 169.73B | 161.91B | 168.38B | 177.76B | 178.33B | 153.39B | 135.42B | 120.40B |
| Interest Income | 89.36M | 153.52M | 215.12M | 343.94M | 406.21M | 615.69M | 271.53M | 242.00M | 196.30M | 340.41M | 366.82M | 325.10M | 309.06M | 1.40B | 1.57B | 1.08B | 702.74M |
| Interest Expense | 4.43B | 1.76B | 141.92M | 41.75M | 24.15M | 34.89M | 145.16M | 427.32M | 911.56M | 1.35B | 1.92B | 1.73B | 2.38B | 2.70B | 2.99B | 2.78B | 1.96B |
| Depreciation & Amortization | 16.61B | 9.82B | 7.36B | 6.49B | 6.47B | 6.26B | 6.63B | 6.92B | 6.54B | 6.10B | 5.36B | 4.08B | 3.24B | 2.89B | 2.35B | 2.27B | 2.32B |
| EBITDA | 36.60B | 33.00B | 41.27B | 39.36B | 27.58B | 66.34B | 53.25B | 46.29B | 42.05B | 37.61B | 35.90B | 20.87B | 27.48B | 26.27B | 15.26B | 14.84B | 16.85B |
| EBITDA Ratio | 12.53% | 12.34% | 16.64% | 16.73% | 11.85% | 25.58% | 21.78% | 20.44% | 19.71% | 18.83% | 18.73% | 11.28% | 13.67% | 13.11% | 9.23% | 10.02% | 12.23% |
| Operating Income | 20.48B | 23.18B | 33.91B | 32.24B | 22.21B | 59.54B | 46.95B | 42.06B | 35.97B | 31.58B | 30.09B | 17.32B | 23.91B | 22.08B | 12.00B | 12.58B | 16.71B |
| Operating Income Ratio | 7.01% | 8.46% | 13.56% | 13.71% | 9.18% | 22.90% | 19.14% | 17.57% | 16.61% | 15.69% | 15.67% | 9.33% | 11.85% | 11.02% | 7.26% | 8.50% | 12.19% |
| Total Other Income/Expenses | -4.89B | 2.04B | -402.32M | 587.62M | -23.02B | 508.47M | -474.12M | -3.11B | -1.37B | -1.42B | -1.47B | -2.26B | -2.05B | -6.43B | -2.08B | -2.79B | -4.15B |
| Income Before Tax | 15.60B | 25.23B | 34.91B | 32.83B | 21.87B | 60.05B | 46.47B | 38.94B | 34.59B | 30.16B | 28.62B | 15.06B | 21.86B | 15.65B | 9.92B | 9.79B | 12.57B |
| Income Before Tax Ratio | 5.34% | 9.21% | 13.96% | 13.96% | 9.04% | 23.09% | 18.95% | 16.27% | 15.98% | 14.98% | 14.91% | 8.11% | 10.83% | 7.81% | 6.00% | 6.62% | 9.16% |
| Income Tax Expense | -3.35B | 3.33B | 6.51B | 4.95B | 9.99B | 34.52B | 10.68B | 8.77B | 7.55B | 9.44B | 20.75B | 4.42B | 14.79B | 5.18B | 2.88B | 3.06B | 6.13B |
| Net Income | 18.91B | 21.89B | 28.40B | 27.88B | 11.88B | 25.53B | 35.80B | 30.17B | 27.04B | 20.72B | 7.88B | 10.64B | 7.06B | 10.48B | 7.04B | 6.73B | 6.43B |
| Net Income Ratio | 6.47% | 7.99% | 11.36% | 11.86% | 4.91% | 9.82% | 14.59% | 12.61% | 12.49% | 10.29% | 4.10% | 5.73% | 3.50% | 5.23% | 4.26% | 4.55% | 4.69% |
| EPS | 1.46K | 1.73K | 2.31K | 2.27K | 917.07 | 2.08K | 2.89K | 2.42K | 2.17K | 1.66K | 627.00 | 817.00 | 542.00 | 817.00 | 548.87 | 525.07 | 496.85 |
| EPS Diluted | 1.46K | 1.73K | 2.31K | 2.27K | 917.07 | 2.08K | 2.89K | 2.42K | 2.17K | 1.66K | 627.00 | 817.00 | 542.00 | 817.00 | 548.87 | 525.07 | 496.85 |
| Weighted Avg Shares Out | 12.95M | 12.67M | 12.30M | 12.30M | 12.30M | 12.30M | 12.38M | 12.45M | 12.45M | 12.45M | 12.56M | 13.02M | 13.02M | 12.82M | 12.84M | 12.82M | 12.95M |
| Weighted Avg Shares Out (Dil) | 12.95M | 12.67M | 12.30M | 12.30M | 12.30M | 12.30M | 12.38M | 12.45M | 12.45M | 12.45M | 12.56M | 13.02M | 13.02M | 12.82M | 12.84M | 12.82M | 12.95M |
Source: https://incomestatements.info
Category: Stock Reports